Preferred Name |
Auranofin |
|
Synonyms |
AURANOFIN Auranofin Ridaura |
|
Definitions |
An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65242 |
|
CAS_Registry |
34031-32-8 |
|
CHEBI_ID |
CHEBI:2922 |
|
Chemical_Formula |
C20H34AuO9PS |
|
code |
C65242 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC |
|
DEFINITION |
An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis. |
|
Display_Name |
Auranofin |
|
FDA_UNII_Code |
3H04W2810V |
|
FULL_SYN |
AURANOFIN Auranofin Ridaura |
|
Has_Target | ||
Is_Value_For_GDC_Property | ||
label |
Auranofin |
|
Legacy Concept Name |
Auranofin |
|
Maps_To |
Auranofin |
|
NCI_Drug_Dictionary_ID |
710355 |
|
PDQ_Closed_Trial_Search_ID |
710355 |
|
PDQ_Open_Trial_Search_ID |
710355 |
|
Preferred_Name |
Auranofin |
|
prefixIRI |
Thesaurus:C65242 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0699923 |
|
subClassOf |